 After a subject completes the study, he or she may be eligible to enter study MEK114375, an open-label rollover study of trametinib no wash-out period or follow-up visit required and continue receiving trametinib. For those subjects who wish to discontinue or complete the current study and choose not enter the rollover study, a follow-up visit should be performed within 21 days after receiving the last dose of study treatment. 